WHO Condemns Unethical Hepatitis B Birth Dose Vaccine Trial

The World Health Organization (WHO) has expressed serious concerns regarding a proposed randomized controlled trial (RCT) examining the hepatitis B birth dose vaccine in Guinea-Bissau. The trial, which would withhold the vaccine from a control group, has sparked ethical debate within the global health community, particularly given the established efficacy and safety of the vaccine in preventing mother-to-child transmission of this potentially life-threatening virus. This controversy underscores the delicate balance between scientific inquiry and the fundamental obligation to protect vulnerable populations, especially newborns.

Hepatitis B is a viral infection that attacks the liver, leading to both acute and chronic disease. According to the WHO, an estimated 254 million people were living with chronic hepatitis B infection in 2022, with 1.2 million new infections occurring each year. The virus is most commonly transmitted from mother to child during birth, but also through contact with infected blood or other bodily fluids. Without intervention, a significant proportion of those infected at birth will develop chronic infection, increasing their risk of cirrhosis and liver cancer. The birth dose vaccine, administered within 24 hours of birth, is a cornerstone of prevention efforts, offering nearly 100% protection against the virus. More than 115 countries currently include the hepatitis B birth dose in their national immunization schedules.

Ethical Concerns at the Forefront

The WHO’s concerns center on the ethical implications of withholding a proven, life-saving intervention from newborns. The organization argues that a study design that deliberately exposes participants to the risk of infection, when a safe and effective preventative measure exists, is ethically unacceptable. This position is rooted in the principle of beneficence – the obligation to act in the best interests of patients – and the principle of non-maleficence – the obligation to do no harm. The WHO statement highlights that placebo-controlled trials are only justifiable when no proven intervention is available or when the study design is essential to answer a critical question of efficacy or safety, neither of which appears to be the case here.

Specifically, the WHO points to the potential for serious and irreversible harm to newborns who would not receive the vaccine as part of the trial. Hepatitis B infection in newborns carries a high risk of chronic infection, which can lead to cirrhosis, liver cancer, and death. The organization also questions the scientific justification for the study, noting that publicly available descriptions do not demonstrate a credible safety signal that would warrant exposing participants to such risks. The single-blind, no-treatment-controlled design raises concerns about potential bias and the interpretability of the study results. The WHO emphasizes that resource constraints cannot be used to justify withholding proven care in a research setting.

Guinea-Bissau’s Context and the Path Forward

Guinea-Bissau recently made the decision to add the hepatitis B birth dose to its national immunization schedule, with planned implementation by 2028. This decision underscores the country’s recognition of the vaccine’s value in protecting its population. Although, the country faces significant challenges in implementing comprehensive immunization programs, including logistical hurdles related to cold chain management and reaching remote populations. According to data from 2022, over 12% of adults in Guinea-Bissau are estimated to be living with chronic hepatitis B, and the infection rate in children under five, at around 2% in 2020, is significantly higher than the global target of ≤0.1%.

The proposed trial emerged against this backdrop, aiming to evaluate the potential safety and efficacy of different hepatitis B vaccination strategies. However, the WHO’s concerns prompted Guinea-Bissau to suspend the study pending further technical reviews. The WHO has offered its support to Guinea-Bissau in accelerating the introduction of the birth dose and strengthening implementation through a range of measures, including ensuring timely delivery within 24 hours of birth, implementing antenatal screening for hepatitis B surface antigen (HBsAg), and providing training for healthcare workers. Effective cold chain management and robust monitoring of coverage and pharmacovigilance are also crucial components of a successful program.

The Global Fight Against Hepatitis B

The controversy surrounding the trial in Guinea-Bissau highlights the broader challenges in the global fight against hepatitis B. While the birth dose vaccine is highly effective, access to vaccination remains unevenly distributed, particularly in low- and middle-income countries. According to the WHO, the burden of infection is highest in the Western Pacific and African regions, with 97 million and 65 million chronically infected individuals, respectively. In 2022, hepatitis B resulted in an estimated 1.1 million deaths worldwide, primarily from cirrhosis and hepatocellular carcinoma.

The WHO is committed to working with national authorities, researchers, and partners to ensure that all newborns receive timely protection against hepatitis B. This includes supporting countries in strengthening their immunization programs, improving access to diagnostic testing and treatment, and raising awareness about the importance of prevention. The organization emphasizes the demand for research to be conducted in accordance with the highest ethical and scientific standards, prioritizing the well-being of participants and ensuring that interventions are evidence-based and effective. The long-term goal is to eliminate hepatitis B as a public health threat, but achieving this requires sustained commitment, collaboration, and a focus on equitable access to prevention and treatment.

Understanding the Risks of Mother-to-Child Transmission

Mother-to-child transmission (MTCT) is the most common route of infection for hepatitis B in many parts of the world. Approximately 90% of infants infected during childbirth become chronic carriers of the virus, facing a lifetime risk of developing serious liver disease. This is why the birth dose vaccine is so critical – it effectively breaks the chain of transmission and prevents the vast majority of these infections. Without the vaccine, these infants are at a significantly increased risk of developing cirrhosis, liver cancer, and premature death. The vaccine works by stimulating the infant’s immune system to produce antibodies against the hepatitis B virus, providing long-lasting protection.

The WHO recommends that all infants receive the hepatitis B birth dose, regardless of their mother’s hepatitis B status. However, in settings where the birth dose is not universally available, infants born to mothers who are positive for the hepatitis B surface antigen (HBsAg) should receive hepatitis B immunoglobulin (HBIG) and the hepatitis B vaccine within 24 hours of birth. HBIG provides immediate, passive immunity, while the vaccine provides long-term, active immunity. This combination of HBIG and vaccine is highly effective in preventing MTCT, even in mothers with high viral loads.

The situation in Guinea-Bissau, with a high prevalence of chronic hepatitis B and a relatively recent decision to introduce the birth dose vaccine, underscores the importance of prioritizing access to this life-saving intervention. The WHO’s support in strengthening the country’s immunization program will be crucial in ensuring that all newborns receive the protection they deserve. The suspension of the controversial trial demonstrates a commitment to ethical research practices and a recognition of the paramount importance of protecting vulnerable populations.

The WHO remains steadfast in its commitment to global hepatitis B elimination, advocating for universal access to vaccination, screening, and treatment. The organization continues to work with countries around the world to develop and implement national hepatitis B strategies, monitor progress, and address emerging challenges. The ultimate goal is to create a world free from the burden of hepatitis B, where all individuals have the opportunity to live long and healthy lives.

Further updates on the situation in Guinea-Bissau and the WHO’s global hepatitis B strategy are expected in the coming months. Readers are encouraged to share their thoughts and perspectives on this important issue in the comments section below.